Search
isatuximab isatuximab-irfc (Sarclisa)
Indications:
- relapsed/refractory multiple myeloma*
* for use in combination with pomalidomide (Pomalyst) & dexamethasone, in patients whose disease progressed on at least two prior therapies, including both lenalidomide (Revlimid) & a proteasome inhibitor
Mechanism of action:
- CD38 inhibitor
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
Related
daratumumab (Darzalex)
General
antineoplastic monoclonal antibody
References
- Bankhead C
New Myeloma Drug Wins FDA Approval - Isatuximab-irfc, second
approved anti-CD38 drug, indicated for third-line use and beyond.
MedPage Today March 2, 2020
https://www.medpagetoday.com/hematologyoncology/myeloma/85185